Alumis is a biotechnology company focused on developing treatments for autoimmune disease, and their goal is to create therapies that are more precise than currently available autoimmune or immune-mediated disease treatments. Alumis was founded in 2021 and is headquartered in San Francisco, CA. Through its data analytics platform, Alumis seeks to enable researchers to match the right patients to targets, molecules, and combinations so they can create the best possible outcomes.

Register for Details

For more details on financing and valuation for Alumis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Alumis

Forge green plus iconForge green minus icon

What is Alumis's funding to date?

Alumis has raised $638.43MM to date.
Forge green plus iconForge green minus icon

When was Alumis founded?

Alumis was founded in 2021.

Who are Alumis's major investors?

Foresite Capital
Cormorant Asset Management
Ally Bridge Group
Samsara Biocapital
venBio
Lilly Asia Ventures
Piper Sandler
HBM Healthcare Investments
SR One Capital Management
Omega Funds
Matrix Capital Management
NexTech

Alumis funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
3/6/2024

Series C and C-1

$259MM raised $XXX.XX $XXX.XX
5/8/2023

Series B-2 and B-2A

$98.89MM raised $XXX.XX $XXX.XX
1/6/2022

Series B

$201MM raised $XXX.XX $XXX.XX
5/5/2021

Series A and B-1

$69.04MM raised $XXX.XX $XXX.XX
1/29/2021

Series Seed

$10.5MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.